戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ciated with 2'-C-cyano-2',3'-didehydro-2',3'-dideoxycytidine.
2 sitivity to the mitochondrial toxicant 2'-3'-dideoxycytidine.
3 approved for human use: azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosine; 2', 3'-didehydro-3
4 ed series, L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine 24 and 5-fluorocytidine 26 showed highly
5 decyl-2-O-palmitoyl-1-thioglycerol (2) 2',3'-dideoxycytidine 5'-diphosphate-rac-1-S-octadecyl-2-O-pal
6 yphenyl ether, the target 4'-C-ethynyl-2',3'-dideoxycytidine analogue (rac-1h) was obtained after 13
7 ce of reverse transcriptase inhibitors 2',3'-dideoxycytidine and a tetrahydroimidazo[4,5,1-jk](1,4)-b
8 aused by HIV/AIDS antiretroviral [ddC (2',3'-dideoxycytidine)] and anticancer (oxaliplatin) chemother
9     In contrast, 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 3'-azidothymidine, which are known
10 nti-human immunodeficiency virus agent 2',3'-dideoxycytidine (approximately 6-fold) and the anti-hepa
11  synthetic heteropolymeric RNA template with dideoxycytidine at its 3'-end, we examined de novo initi
12                                         On a dideoxycytidine-blocked synthetic RNA template derived f
13  20% of normal levels by treating with 2',3'-dideoxycytidine (ddC) and subsequently allowed recovery
14                                        2',3'-dideoxycytidine (ddC) is a synthetic pyrimidine nucleosi
15 odified cytosine analogs, Zalcitabine (2',3'-dideoxycytidine (ddC)) and Lamivudine (beta-d-(+)-2',3'-
16 idehydro-2',3'-dideoxythymidine (D4T), 2',3'-dideoxycytidine (ddC), (-)-beta-L-2',3'-dideoxy-3'-thiac
17 o the mtDNA depletion caused by beta-d-2',3'-dideoxycytidine (ddC), 2',3'-didehydro-2',3'-dideoxythym
18 de D-nucleoside analogs such as beta-D-2',3'-dideoxycytidine (ddC), beta-2'-fluoro-5-methyl-arabinofu
19 cellular tolerance to CTNAs, including 2',3'-dideoxycytidine (ddC), cytarabine (ara-C) and zidovudine
20  The first-generation NRTIs, including 2',3'-dideoxycytidine (ddC), were originally and are still pur
21                                              Dideoxycytidine (ddC), which is known to have a delayed
22 y activity, we used a nucleoside analog 2'3'-dideoxycytidine (ddC), which is phosphorylated to the ac
23 ally exhibited low-level resistance to 2',3'-dideoxycytidine (ddC).
24 -5-fluorocytidine (beta-L-FddCTP) and 2', 3'-dideoxycytidine (ddCTP), on DNA strand elongation by hum
25 ing resistance to tenofovir, abacavir, 2',3'-dideoxycytidine, dideoxyinosine, and stavudine.
26 2',3'-dideoxy-3'-thiocytidine > beta-d-2',3'-dideoxycytidine > beta-d-2',2'-difluorodeoxycytidine > b
27 3'-didehydro-5-fluorocytidine > beta-l-2',3'-dideoxycytidine > beta-l-2',3'-dideoxy-3'-thiocytidine >
28 d an 82-fold increase in the IC(50) to 2',3'-dideoxycytidine in Jurkat cells.
29 ited antinociception in a zalcitabine (2'-3'-dideoxycytidine) model of AIDS therapy-induced and tibia
30          The L-enantiomers of 5-fluoro-2',3'-dideoxycytidine monophosphate and triphosphate had IC50
31 olled in a prospective trial of zalcitabine (dideoxycytidine) monotherapy (Pediatric AIDS Clinical Tr
32 everse transcriptase inhibitor (NRTI), 2',3'-dideoxycytidine or 2',3'-dideoxyinosine, mtDNA depletion
33 othymidine therapy in combination with 2',3'-dideoxycytidine or 2',3'-dideoxyinosine.
34 ylated to the activated antimetabolite, 2'3'-dideoxycytidine triphosphate by cytoplasmic nucleoside k
35  I (Klentaq1) with a primer/template DNA and dideoxycytidine triphosphate, and that of a binary compl
36 ion therapy with zidovudine (AZT) plus 2',3'-dideoxycytidine was found to regain sensitivity to AZT a
37 ',3'-dideoxy-3'-thiacytidine) and ddC (2',3'-dideoxycytidine) were added to the cultures beginning at
38 V inhibition by azidothymidine (zidovudine), dideoxycytidine (zalcytibine), and hydroxyurea.